Tarceva Effective in Asians with Specific Form of Lung Cancer

In a Phase II trial, Roche’s Tarveca greatly increased survival among patients with a specific form of non-small cell lung cancer (NSLC), advanced lung adenocarcinoma. The drug was especially potent among patients who have epidermal growth factor receptor (EGFR) activating mutations. NSLC with EGFR activating mutations is a genetically distinct form of lung cancer that is most common in patients who have never smoked, patients with adenocarcinoma, people of Asian origin and females. More details... Stock Symbol: (SVX: ROG)